A phase II, multicenter, randomized, open-label study to evaluate the safety and tolerability of proxalutamide (GT0918) in subjects with metastatic castrate-resistant prostate cancer (mCRPC).

被引：1

作者：

Zhou, Tie ^{[1
]}

Ye, Dingwei ^{[2
]}

Sun, Zhongquan ^{[3
]}

Meng, Qinggui ^{[4
]}

He, Dalin ^{[5
]}

Shi, Guowei ^{[6
]}

Jin, Jie ^{[7
]}

Sun, Weibing ^{[8
]}

Chen, Lijun ^{[9
]}

Liu, Ben ^{[10
]}

Wang, Jingen ^{[11
]}

Cheng, Jiwen ^{[12
]}

Hu, Zhiquan ^{[13
]}

Yang, Yong ^{[14
]}

Song, Xishuang ^{[15
]}

Wang, Yinhuai ^{[16
]}

Fu, Cheng ^{[17
]}

Zhou, Qiaoxia ^{[18
]}

Tong, Youzhi ^{[18
]}

Sun, Ying-Hao ^{[1
]}

机构：

[1] Shanghai Changhai Hosp, Shanghai, Peoples R China

[2] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China

[3] Shanghai Huadong Hosp, Shanghai, Peoples R China

[4] Guangxi Zhuang Autonomous Reg Canc Hosp, Nanning, Guangxi, Peoples R China

[5] Xi An Jiao Tong Univ, Affiliated Hosp 1, Xian, Peoples R China

[6] Fudan Univ, Shanghai Peoples Hosp 5, Shanghai, Peoples R China

[7] Peking Univ First Hosp, Beijing, Peoples R China

[8] Dalian Med Univ, Hosp 2, Dalian, Peoples R China

[9] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 5, Beijing, Peoples R China

[10] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Hangzhou, Peoples R China

[11] Jiangxi Prov Peoples Hosp, Nanchang, Jiangxi, Peoples R China

[12] Guangxi Med Univ, Affiliated Tumor Hosp, Nanning, Peoples R China

[13] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Wuhan, Peoples R China

[14] Beijing Canc Hosp, Beijing, Peoples R China

[15] Dalian Med Univ, Affiliated Hosp 1, Dalian, Peoples R China

[16] Cent South Univ, Xiangya Hosp 2, Changsha, Peoples R China

[17] Liaoning Tumour Hosp, Shenyang, Peoples R China

[18] Kintor Pharmaceut Ltd, Suzhou, Peoples R China

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 06期

关键词：

D O I：

10.1200/JCO.2021.39.6_suppl.108

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

108

引用

页数：2